| Cat.No. | Name | Information |
|---|---|---|
| M50166 | ZL-1218 | ZL-1218 is a novel anti-CCR8 antibody that can be used in studies related to solid tumors. |
| M50165 | HBM1022 | HBM1022 is an anti-CCR8 fully human monoclonal antibody for use in studies related to solid tumors. |
| M50164 | CM369 | CM369 is a potential first-of-its-kind (first-in-class) anti-chemokine receptor 8 (CCR8) monoclonal antibody that binds specifically to CCR8 on Treg and removes immunosuppressive Treg through ADCC action to relieve tumor suppression in the TME.CM369 can be used in studies related to advanced solid tumors. |
| M50163 | BGB-A3055 | BGB-A3055 is a monoclonal antibody targeting CCR8 for studies related to solid tumors. |
| M50162 | AMG-355 | AMG-355 is a monoclonal antibody targeting CCR8 for studies related to solid tumors. |
| M50160 | SRF-114 | SRF-114 is a human IgG1 anti-CCR8 monoclonal antibody that targets tumor Treg cells and induces antibody-dependent cell-mediated cytotoxicity (ADCC) through activation of NK cells, resulting in selective depletion of immunosuppressive tumor T regulatory cells (Tregs) while preserving peripheral Tregs. It can be used for tumor-related studies. |
| M50159 | S-531011 | S-531011 is a novel anti-human IgG1 antibody that exhibits in vitro antibody-dependent cytotoxicity against CCR8-expressing cells and neutralizing activity against the CCL1-CCR8 signaling pathway. It can be used in studies related to solid tumors. |
| M50158 | LM-108 | LM-108 is a novel anti-CCR8 monoclonal antibody that efficiently eliminates tumor-associated Tregs in a mouse model through antibody-dependent cell-mediated cytotoxicity (ADCC) without affecting peripheral Tregs, showing potent anti-tumor activity, and can be used for tumor-related studies. |
| M50155 | DT-7012 | DT-7012 is a potential best-in-class (BIC) monoclonal antibody that effectively depletes the anti-CCR8 receptor of tumor-infiltrating regulatory T cells (Tregs) for use in studies related to cutaneous T-cell lymphoma (CTCL) and solid tumors. |
| M49947 | Ifabotuzumab | Ifabotuzumab is an IgG1κ antibody (KD=610 pM) targeting EphA3. Ifabotuzumab is able to cause apoptosis of tumor cells and activate antibody-dependent cell-mediated cytotoxicity (ADCC), which disrupts the tumor vascular system. In addition, Ifabotuzumab reduces idiopathic pulmonary fibrosis (IPF) CCR10+ cells and ameliorates pulmonary fibrosis. |
| M49472 | LY3164530 | LY3164530 is a bispecific antibody targeting c-MET/EGFR that fuses scFv (cetuximab) to the N-terminal end of the heavy chain of emibetuzumab, resulting in a 2+2 symmetric bis-antibody, which is of the IgG4 subtype, and has little to no associated effects such as ADCC. |
| M49470 | MCLA-129 | MCLA-129 is a 1+1 asymmetric c-Met/EGFR bispecific antibody that can be used in a variety of tumor-related studies. |
| M49469 | CKD-702 | CKD-702 is a c-Met/EGFR bispecific antibody that can be used in studies related to non-small cell lung cancer and gastric cancer. |
| M49455 | CALY-002 | CALY-002 is a potential best-in-class (BIC), humanized monoclonal antibody targeting IL-15 for studies related to immune diseases. |
| M49447 | GS-1811 | GS-1811 is a monoclonal antibody targeting CCR8 that selectively removes tumor-infiltrating T regulatory cells with immunosuppressive effects in the tumor microenvironment, and can be used in studies related to solid tumors. |
| M49444 | BAY-3375968 | BAY-3375968 is a monoclonal antibody targeting the CCR8 receptor that selectively reduces CCR8-positive Tregs through antibody-dependent cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), and can be used in studies related to solid tumors. |
| M49442 | BMS-986340 | BMS-986340 is a human immunoglobulin G1 (IgG1) non-fucosylated (NF) monoclonal antibody to CCR8 that targets, binds to, and blocks CCR8 activity on CCR8-positive tumor-infiltrating regulatory T-cells (Tregs) in tumor microenvironments (TMEs) and prevents chemokine ligand (CCL1-CCR8)-mediated signaling. |
| M49437 | PF-06480605 | PF-06480605 is an IgG1 human monoclonal antibody against TNF-like ligand 1A (TL1A, TNFSF15), which can be used in studies related to ulcerative colitis (UC). |
| M49436 | V565 | V565 is a novel antibody that specifically targets TNFα and can be used in studies related to Crohn's disease (CD). |
| M49354 | Auremolimab | Auremolimab is an ultra-humanized monoclonal antibody against IL-2Rβ (CD122) that targets and depletes tissue-resident memory T-cells, and may be used in vitiligo-related studies. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
